<Li> Key: JUZNIMUFDBIJCM - ANEDZVCMSA - N </Li> <Tr> <Th_colspan="2"> (what is this?) (verify) </Th> </Tr> <P> Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz . It is structurally very similar to meropenem in that it possesses a 1 - β - methyl group . Other members of the carbapenem group (imipenem, doripenem, and meropenem) are broadly active antibacterials that are used for infections caused by difficult to treat or multidrug - resistant bacteria (such as ESBL expressing Klebsiella pneumonia). They have very short serum half - lives and must be administered by intravenous infusion every 6 to 8 hours . Ertapenem differs from other carbapenems in having a somewhat less broad spectrum of activity (not against Pseudomonas aeruginosa), and in that its extended serum half - life allows it to be administered once every 24 hours . </P> <P> Ertapenem has been designed to be effective against Gram - negative and Gram - positive bacteria . It is not active against MRSA, ampicillin - resistant enterococci, Pseudomonas aeruginosa, or Acinetobacter species . Ertapenem also has clinically useful activity against anaerobic bacteria . </P>

How long does invanz stay in your system